Skip to main content
SpringerLink
Log in

Future of monoclonal antibodies in solid organ transplantation

  • Review Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

The ultimate objective of immunosuppressive therapy is to block transplant recipient reactivity to allograft incompatibilities while sparing other responses. Increased clarification of rejection mechanisms has made possible the precise suppression of specific elements of the immune response using murine anti-human monoclonal antibodies. In addition, recombinant DNA technology has made available novel agents including “humanized,” bispecific, or toxin-conjugated molecules, which avoid some of the limitations of murine reagents. Using such agents, donor-specific tolerance has been induced in experimental models after a limited course of therapy directed against selected effector cell surface-associated molecules such as CD4, CD25, and CD54. It remains to be determined how such observations can be successfully transferred to the human situation. It seems likely, however, that as new molecular agents are developed, increasingly effective suppression of specific cellular targets will become an essential element of clinical protocols. Such agents may provide long-term immunosuppression with limited periods of immunosuppressive agent administration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cosimi AB, Colvin RB, Burton RC, Rubin RH, Goldstein G, Kung PC, Hansen WP, Delmonico FL, Russell PS: Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 305:308–314, 1981

    PubMed  Google Scholar 

  2. Cosimi AB, Burton RC, Colvin RB, Goldstein G, Delmonico FL, LaQuaglia MP, Tolkoff-Rubin RH, Herrin JT, Russell PS: Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 32:535–539, 1981

    PubMed  Google Scholar 

  3. Cosimi AB: Anti-T-cell monoclonal antibodies in transplantation therapy. Transplant Proc 15:1889–1892, 1983

    Google Scholar 

  4. Frenken LAM, Hoistma AJ, Tax WJM, Koene RAP: Prophylactic use of anti-CD3 monoclonal antibody WT32 in kidney transplantation. Transplant Proc 23:1072–1073, 1991

    PubMed  Google Scholar 

  5. Waid TH, Lucas BA, Thompson JS, Brown SA, Munch L, Prebeck RJ, Jezek D: Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients. Transplantation 53:80–86, 1992

    PubMed  Google Scholar 

  6. Sablinski T, Sayegh MH, Kut JP, Tilney NL, Milford EL, Kupiec-Weglinski JW: The importance of targeting the CD4 + T-cell subset at the time of antigenic challenge for induction of prolonged vascularized allograft survival. Transplantation 53:219–221, 1992

    PubMed  Google Scholar 

  7. Shizuru JA, Seydel KB, Flavin TF, Wu AP, Kong CC, Hoyt EG, Fujimoto N, Billingam ME, Starnes VA, Fathman CG: Induction of donor specific unresponsiveness to cardiac allografts in rats by pretransplant anti-CD4 monoclonal antibody therapy. Transplantation 50:366–373, 1990

    PubMed  Google Scholar 

  8. Sablinski T, Hancock WW, Tilney NL, Kupiec-Weglinski JW: CD4 monoclonal antibodies in organ transplantation—a review of progress. Transplantation 52:579–589, 1991

    PubMed  Google Scholar 

  9. Cosimi AB, Delmonico FL, Wright JK, Wee SL, Preffer FI, Jolliffe LK, Colvin RB: Prolonged survival of nonhuman primate renal allograft recipients treated only with anti-CD4 monoclonal antibody. Surgery 108:406–414, 1990

    PubMed  Google Scholar 

  10. Wee SL, Stroka DM, Preffer FI, Jolliffe LK, Colvin RB, Cosimi AB: The effects of OKT4A monoclonal antibody on cellular immunity of nonhuman primate renal allograft recipients. Transplantation 53:501–507, 1992

    PubMed  Google Scholar 

  11. Darby CR, Morris PJ, Wood KJ: Evidence that long-term cardiac allograft survival induced by anti-CD4 monoclonal antibody does not require depletion of CD4+ T cells. Transplantation 54:483–490, 1992

    PubMed  Google Scholar 

  12. Delmonico FL, Cosimi AB, Kawai T, Cavender D, Lee WH, Joliffe LK, Knowles RW: Non-human primate responses to murine and humanized OKT4A. Transplantation 55:722–728, 1993

    PubMed  Google Scholar 

  13. Land W: Monoclonal antibodies in 1991: New potential options in clinical immunosuppressive therapy. Clin Transplant 5:493–500, 1991

    Google Scholar 

  14. Reichart B, Meiser BM, Reiter CH, Wene K, Reichenspurner H, Kreizer E, Riethmuller G, Uberfuhr P: A new chimeric monoclonal CD4 antibody for heart and heart-lung transplantation. Transplantation (in press)

  15. Horneff G, Burmester GR, Emmrich F, Kalden JR: Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 34:129–131, 1991

    PubMed  Google Scholar 

  16. Kupiec-Weglinski JW, Diamantstein T, Tilney NL: Interleukin-2 receptor-targeted therapy—rationale and applications in organ transplantation. Transplantation 46:785–792, 1988

    PubMed  Google Scholar 

  17. Kirkman RL, Shapiro ME, Carpenter CB, McKay DB, Milford EL, Ramos EL, Tilney NL, Waldmann TA, Zimmerman CE, Strom TB: A randomized prospective trial of anti-TAC monoclonal antibody in human renal transplantation. Transplantation 51:107–113, 1991

    PubMed  Google Scholar 

  18. Soulillou J-P, Cantarovich D, Le Mauff B, Giral M, Robillard N, Hourmant M, Hirn M, Jacques Y: Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 322:1175–1182, 1990

    PubMed  Google Scholar 

  19. Hiesse C, Kriaa F, Alard P, Lantz O, Noury J, Bensadoun H, Benoit G, Charpentier B, Fries D, Bazin H: Prophylactic use of the IL-2 receptor-specific monoclonal antibody LO-Tact-1 with cyclosporin A and steroids in renal transplantation. Transplant Int 5 (suppl. 1) 444–447, 1992

    Google Scholar 

  20. Friend PJ, Waldmann H, Cobbold S, Tighe H, Rebello P, Wight D, Gore S, Pollard S, Lim S, Johnston P, Williams R, O'Grady J, Calne RY: The anti-IL-2 receptor monoclonal antibody YTH-906 in liver transplantation. Transplant Proc 23:1390–1392, 1991

    PubMed  Google Scholar 

  21. Kirkman RL, Bacha P, Barrett LV, Forte S, Murphy JR, Strom TB: Prolongation of cardiac allograft survival in murine recipients treated with a diphtheria toxin-related interleukin-2 fusion protein. Transplantation 47:327–330, 1989

    PubMed  Google Scholar 

  22. Cosimi AB, Conti D, Delmonico FL, Preffer FI, Wee SL, Rothlein R, Faanes R, Colvin RB:In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts. J Immunol 144:4604–4612, 1990

    PubMed  Google Scholar 

  23. Haug CE, Colvin RB, Delmonico FL, Auchincloss H, Tolkoff-Rubin N, Preffer FI, Rothlein R, Norris S, Scharschmidt L, Cosimi AB: Phase I trial of immunosuppression with anti-ICAM-1 (CD54) MAb in renal allograft recipients. Transplantation 55:766–773, 1993

    PubMed  Google Scholar 

  24. Isobe M, Yagita H, Okumura K, Ihara A: Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 255:1125–1127, 1992

    PubMed  Google Scholar 

  25. Nakakura E, Jardieu P, McCabe S, Scheiner T, Shorthouse R, Zheng B, Morris RE: A non-lymphocyte depleting monoclonal antibody to the adhesion molecule LFA-1 inhibits ongoing and accelerated rejection and induces unresponsiveness to heart allografts. Transplant Proc 25:809–812, 1993

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. From the Transplantation Unit, Massachusetts General Hospital, and the Department of Surgery, Harvard Medical School, 02114, Boston, Massachusetts

    A. Benedict Cosimi MD

Authors
  1. A. Benedict Cosimi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported by U.S. Public Health Service Grant HL-18646 and by funds from the Ortho Pharmaceutical Corporation, Raritan, New Jersey, and Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cosimi, A.B. Future of monoclonal antibodies in solid organ transplantation. Digest Dis Sci 40, 65–72 (1995). https://doi.org/10.1007/BF02063943

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02063943

Key words

Search

Navigation